BridgeBio Pharma, Inc.
BBIO
$76.08
$1.321.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 120.39% | 66.78% | 2,521.18% | 4,318.01% | 4,999.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 120.39% | 66.78% | 2,521.18% | 4,318.01% | 4,999.86% |
| Cost of Revenue | 311.88% | 276.62% | 289.01% | 997.49% | 510.87% |
| Gross Profit | 113.85% | 61.92% | 3,746.00% | 5,248.50% | 6,709.68% |
| SG&A Expenses | 44.22% | 54.09% | 66.79% | 99.98% | 116.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.73% | 36.31% | 24.38% | 35.39% | 39.60% |
| Operating Income | 19.77% | -2.08% | 41.97% | 27.13% | 22.69% |
| Income Before Tax | 14.18% | 1.80% | 26.85% | -13.53% | -140.47% |
| Income Tax Expenses | -- | -- | -110.41% | -- | -- |
| Earnings from Continuing Operations | 15.17% | 1.80% | 27.21% | -12.59% | -143.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 98.11% | 14.91% | -24.24% | -0.90% | -11.16% |
| Net Income | 16.32% | 2.02% | 27.24% | -12.78% | -147.64% |
| EBIT | 19.77% | -2.08% | 41.97% | 27.13% | 22.69% |
| EBITDA | 19.77% | -2.20% | 42.27% | 27.28% | 22.75% |
| EPS Basic | 18.57% | 4.35% | 28.78% | -10.81% | -143.82% |
| Normalized Basic EPS | 17.29% | -9.88% | 31.36% | 17.78% | 11.16% |
| EPS Diluted | 18.57% | 4.35% | 28.78% | -10.81% | -143.82% |
| Normalized Diluted EPS | 17.29% | -9.88% | 31.36% | 17.78% | 11.16% |
| Average Basic Shares Outstanding | 2.77% | 2.44% | 2.17% | 1.77% | 1.56% |
| Average Diluted Shares Outstanding | 2.77% | 2.44% | 2.17% | 1.77% | 1.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |